Jump to content

PH-responsive tumor-targeted drug delivery

Edit links
From Wikipedia, the free encyclopedia

pH-responsive tumor-targeted drug delivery is a specialized form of targeted drug delivery that utilizes nanoparticles to deliver therapeutic drugs directly to cancerous tumor tissue while minimizing its interaction with healthy tissue.[1] Scientists have used drug delivery as a way to modify the pharmacokinetics and targeted action of a drug by combining it with various excipients, drug carriers, and medical devices.[2] These drug delivery systems have been created to react to the pH environment of diseased or cancerous tissues, triggering structural and chemical changes within the drug delivery system.[3] This form of targeted drug delivery is to localize drug delivery, prolongs the drug's effect, and protect the drug from being broken down or eliminated by the body before it reaches the tumor.

Tumor Environment

[edit]

The microenvironment of a tumor is different compared to normal healthy tissues in the body. One distinct difference is the pH levels. The human body overall tends to have a more alkaline pH level of 7.4 while tumor tissue ranges from 7.0- 7.2 pH level, which is known as tumor acidosis.[4] Tumor acidosis can occur due to various factors, including hypoxia, the Warburg effect, and the release of acidic metabolites by the tumor cells.[5]

Tumor hypoxia occurs when a tumor’s environment has low or severely depleted oxygen levels compared to healthy tissue, which could lead to tumor acidosis.[6] Rapidly reproducing tumor cells become more extensive in size and do not have a sufficient blood supply.  Some studies show that this leads tumor environments to become hypoxic, which then leads to metabolic changes.[7]

The Warburg Effect refers to cancer cells using aerobic glycolysis for cell metabolism, which results in an increased rate of glucose uptake and a preference for lactate production, despite the presence of oxygen.[8] It is still unknown why cancer cells switch their metabolism method as it is energy inefficient. Even though this method is inefficient in producing ATP, some studies show that cancer cells may be using aerobic glycolysis to produce energy because it is faster than the normal process of respiration.[8] This process allows these malignant cells to produce energy quickly. This is particularly useful in an environment where they must rapidly grow and divide.[7] The acidic metabolite build-up occurs due to an excess of lactate production.[9]

As a result, targeting the acidic microenvironment of tumors has emerged as a promising strategy for cancer therapy. One approach involves the use of creating drug delivery carriers that are sensitive to pH levels and have triggered drug release at the tumor site, thereby enhancing the efficacy of chemotherapy and other treatments.[10]

Mechanism of pH-responsive tumor-targeted drug delivery

[edit]

Mechanisms

[edit]

pH-responsive tumor-targeted drug delivery detects the changes in the pH within the body. These polymer drug carriers carry the therapeutic drugs to allow for targeted drug delivery. The purpose of the pH- triggered drug release is to deliver the drug precisely to the area of the tumor and not activate and release the drug in healthy tissue.[1] The complex compromises a drug delivery unit made up of a carrier molecule made up of organic nanomaterials, inorganic nanomaterials, composite nanomaterials, and anti-tumor drugs. The carrier compromises pH-sensitive molecules, which allows the drug vehicle to activate at the tumor site at the optimal pH range it is set to get triggered at and release the drug.[11]

The loading of anti-tumor drugs into pH-responsive polymer nanomaterials can be classified into three categories: chemical bonding, intermolecular force, and physical encapsulation.[12] These loading mechanisms allow the drug to stay within the carrier until the tumor environment has been reached. In addition, the carrier can be engineered to have the ability to modify its structure or properties in response to the pH change. Common pH-sensitive structures include chemical bonds that hydrolyze or break in acidic environments, polymers that change their charge properties with pH changes, and other special pH-responsive polymers.[13][11] For example, two possible mechanisms could be applied: incorporating protonatable groups or forming acid-labile bonds. When exposed to the low pH, pH-triggered protonation/ionization changes create disturbances of the hydrophilic-hydrophobic balance within the nanocarrier, causing its disassembly and releasing the drug encapsulated within the carrier.[13] Common ionizable groups used include amino, carboxyl, sulfonate, and imidazolyl. Depending on the introduced functional group's acid dissociation constant (pKa), drug release from these nanocarriers can occur through precipitation, aggregation, or dissociation mechanisms.[10] Another possible carrier could be lipid-based, and a drop in pH can cleave the covalent acid-labile bonds on the surface and within the carrier leading to swelling of the drug delivery system and then release of the drug at a specific rate.[10]

Advantages of pH-responsive tumor-targeted drug delivery

[edit]

Studies have shown pH-responsive tumor-targeted drug delivery carriers to have advantages. One key advantage is the increased specificity targeting the tumor cells and comparatively low cytotoxicity compared to other therapy methods.[14] The low toxicity results from reducing the drug or therapy exposure to healthy tissue due to the targeted approach of this drug delivery method.[15] Another aspect noticed during previous studies is the efficiency in drug release rate. The drug carrier releases the anti-cancer drug when triggered by the tumor's low pH levels and these pH levels control the rate of drug release.[16] Drugs administered usually require frequent dosing, but with a drug delivery carrier, it allows for a gradual and sustained release of the drug leading cancer patients to not have to be in the clinic as much for treatment.[17]

Types of pH- responsive drug delivery vehicles

[edit]

Hydrogel based pH- triggered Drug Delivery

[edit]
Hydrogel Crosslinking

Hydrogels

[edit]

Hydrogels are networks of polymers crosslinked to form a three-dimensional structure capable of absorbing and retaining large amounts of fluids. The polymer chains contain numerous hydrophilic groups such as -NH2, -OH, -COOH, and -SO3. With increased capillary action, hydrogels are relatively insoluble unless triggered by the change in pH for tumor-targeted drug carriers.[18] The physical properties of hydrogels can be adjusted to meet specific requirements for various drug delivery systems. pH-responsive hydrogels have been extensively developed recently and have proven particularly useful for targeted cancer treatment. They can prolong drug release and are quick and cost-effective to synthesize.[12]

PEG-PLGA hydrogel nanoparticles

[edit]

In the past decade, scientists have been working on engineering an injectable hydrogel post- resection surgery to treat tumor sites.[19] Polylactide-co-glycolide (PLGA) and polyethylene glycol (PEG) hydrogel is an injectable biomaterial made up of is a copolymer, that has been approved by the Food and Drug Administration (FDA) for use in therapeutic devices due to its biodegradability and biocompatibility properties in the human body.[20][19] There have been studies done in loading these hydrogels with cancer therapeutic drugs for localized treatment in breast tumors after surgical resection. Additionally, drug-loaded particles within the hydrogel have been proposed as dual-stimuli responsive drug delivery systems combining pH-responsivity with the temperature response of the PEGylated polyester gels. Studies show that these types of hydrogels can be used to treat tumors in lungs and bladders.[19]

Liposome/Micelle based pH- triggered Drug Delivery

[edit]
Liposomes are made of phospholipids and contain small amounts of other molecules. This is one example of a type of drug delivery carrier that can be used for pH-responsive tumor targeted drug delivery.[21]

Liposomes

[edit]

Liposomes were first reported as drug-delivery vehicles in the 1960s and are biomimetic nanosomes composed of phospholipid bilayers. Due to their biocompatibility, biodegradability, and ability to encapsulate both hydrophilic and hydrophobic drugs, liposomes are a popular choice for pH-responsive tumor-targeted drug delivery.[12][22] The liposome can be modified to facilitate triggered release in response to acidic environmental conditions. These can be prepared by adding pH-sensitive components to fabricate liposomes. pH-responsive liposomes generally consist of weakly acidic amphiphile such as cholesteryl hemisuccinate (CHEMS) and cone-shaped lipids such as Dioleoylphosphatidylethanolamine (DOPE).[23] DOPE adopts a bilayer structure at neutral pH but forms a hexagonal inverted structure, due to the low hydration of their polar head and neutralization of the negatively charged phosphodiester groups when exposed to acidic conditions, such as tumour sites, leading to destabilization and content release, while remaining stable at physiological pH.[23][24] pH-responsive liposomes have some significant advantages, such as low toxicity, simple preparation, and good biocompatibility due to the biocompatible degradable components.[12]

Micelles

[edit]
Micelle Diagram

Micelles are typically formed through block polymers self-assembling which can be conjugated with different units, such as polyethylene glycol and poly(amino acid). Drug release from micelles is typically slow, resulting in low concentrations of free drugs in tumor cells and decreased therapeutic outcomes. However, introducing pH-sensitive chemical bonding arms between polymer chain segments or polymers will allow the micelle to hydrolyze quickly under weakly acidic conditions and work as an efficient drug delivery carrier for pH-responsive tumor-targeted drug delivery.[12]

PEGylated doxorubicin nanoparticles

[edit]

PEGylated liposomal doxorubicin has been studied and show results of high drug loading capacity and pH-responsive drug release within the tumor cell or tissue region.[25] Doxorubicin is a widely used anti-cancer drug, but it has sever toxic side effects towards the cancer patients. To mitigate this, scientists are conducting tests to see how fabricating doxorubicin within the liposomal formulation can have an effect on potentially decreasing side effects through covalent bond interactions in the formation of this drug carrier type.[26]

Challenges and future direction

[edit]

pH-triggered drug delivery systems are able to control the pharmacokinetics and the biodistribution of the drugs enclosed within the drug carrier and have a controlled release. Many “smart” pH-responsive drug delivery systems have not made it to clinical trials.[27] However, there still are many challenges with this treatment method.[10] Drug carriers for the pH-triggered release of tumors can be made out of many different combinations of materials depending on the tumor type. One of the popular materials to use is acrylamide or acrylic acid types of polymers. These polymers are harder to degrade in the body as they are not hydrolytically degradable.[27] Another concern is how effective these carriers are in reaching the target areas. There are different methods to create these carriers to maximize the drug delivery at the site, and each method poses its own potential risks to achieve making the drug carrier.[10] Some materials that could be used have higher molecular weights, which will not be able to be excreted via the kidneys after releasing the drug at the target area.[27] This leads to accumulation in the body and can lead to other problems.

Another major current issue is this drug delivery system's low accuracy and off-target delivery. The heterogeneity of the tumor pH is one of the reasons for this cause. The pH of the tumor tends to become more acidic as you reach the center of the tumor.[10] Another reason for off-target delivery could be due to the lower pH levels of lesions and inflammation sites. Studies show that this problem could be overcome by avoiding receptor-mediated active targeting with monoclonal antibodies.[10]

Besides the drugs, conducting clinical trials can also be very expensive.[28] When drug delivery systems tend to have high molecular weight and have a possibility of being toxic to the body due to build-up, companies tend to shy away from taking part in actively testing out these drugs clinically as it can pose a risk for the company in terms of monetary funds as well as ethical issues.[27]

With more research and in vitro and in vivo testing, a possible solution could be found to combat these challenges. This drug delivery treatment method can be used in combination with other cancer treatment methods such as chemotherapy, gene therapy, and a combination of these therapies.[29][30]

References

[edit]
  1. ^ a b Muller, R; Keck, C (2004). "Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles". Journal of Biotechnology. 113 (1–3): 151–170. doi:10.1016/j.jbiotec.2004.06.007...https://www.accessscience.com/content/article/a757275
  2. ^ Tiwari, Gaurav; Tiwari, Ruchi; Sriwastawa, Birendra; Bhati, L; Pandey, S; Pandey, P; Bannerjee, Saurabh K (2012). "Drug delivery systems: An updated review"
  3. ^ Abu-Thabit, Nedal Y.; Makhlouf, Abdel Salam H. (2018-01-01), Makhlouf, Abdel Salam Hamdy; Abu-Thabit, Nedal Y. (eds.), "1 - Historical development of drug delivery systems: From conventional macroscale to controlled, targeted, and responsive nanoscale systems"
  4. ^ Zhang, Xiaomeng; Lin, Yuxiang; Gillies, Robert J. (August 2010). "Tumor pH and Its Measurement". Journal of Nuclear Medicine. 51 (8): 1167–1170. doi:10.2967/jnumed.109.068981. ISSN 0161-5505. PMC 4351768. PMID 20660380.
  5. ^ Pillai, Smitha R.; Damaghi, Mehdi; Marunaka, Yoshinori; Spugnini, Enrico Pierluigi; Fais, Stefano; Gillies, Robert J. (June 2019). "Causes, consequences, and therapy of tumors acidosis". Cancer and Metastasis Reviews. 38 (1–2): 205–222. doi:10.1007/s10555-019-09792-7. ISSN 0167-7659. PMC 6625890. PMID 30911978.
  6. ^ Gilkes, Daniele M.; Semenza, Gregg L.; Wirtz, Denis (June 2014). "Hypoxia and the extracellular matrix: drivers of tumour metastasis". Nature Reviews Cancer. 14 (6): 430–439. doi:10.1038/nrc3726. ISSN 1474-175X. PMC 4283800. PMID 24827502.
  7. ^ a b Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. doi:10.1126/science.1160809
  8. ^ a b Liberti, Maria V.; Locasale, Jason W. (2016-03-01). "The Warburg Effect: How Does it Benefit Cancer Cells?". Trends in Biochemical Sciences. 41 (3): 211–218. doi:10.1016/j.tibs.2015.12.001. ISSN 0968-0004. PMC 4783224. PMID 26778478.
  9. ^ Kato, Yasumasa; Ozawa, Shigeyuki; Miyamoto, Chihiro; Maehata, Yojiro; Suzuki, Atsuko; Maeda, Toyonobu; Baba, Yuh (2013-09-03). "Acidic extracellular microenvironment and cancer". Cancer Cell International. 13 (1): 89. doi:10.1186/1475-2867-13-89. ISSN 1475-2867. PMC 3849184. PMID 24004445.
  10. ^ a b c d e f g AlSawaftah, Nour M.; Awad, Nahid S.; Pitt, William G.; Husseini, Ghaleb A. (2022-02-26). "pH-Responsive Nanocarriers in Cancer Therapy". Polymers. 14 (5): 936. doi:10.3390/polym14050936. ISSN 2073-4360. PMC 8912405. PMID 35267759.
  11. ^ a b Chu, Shunli; Shi, Xiaolu; Tian, Ye; Gao, Fengxiang (2022-03-22). "pH-Responsive Polymer Nanomaterials for Tumor Therapy". Frontiers in Oncology. 12: 855019. doi:10.3389/fonc.2022.855019. ISSN 2234-943X. PMC 8980858. PMID 35392227.
  12. ^ a b c d e Zhuo, Shijie; Zhang, Feng; Yu, Junyu; Zhang, Xican; Yang, Guangbao; Liu, Xiaowen (January 2020). "pH-Sensitive Biomaterials for Drug Delivery". Molecules. 25 (23): 5649. doi:10.3390/molecules25235649. ISSN 1420-3049. PMC 7730929. PMID 33266162.
  13. ^ a b Tang, Houliang; Zhao, Weilong; Yu, Jinming; Li, Yang; Zhao, Chao (2018-12-20). "Recent Development of pH-Responsive Polymers for Cancer Nanomedicine". Molecules. 24 (1): 4. doi:10.3390/molecules24010004. ISSN 1420-3049. PMC 6337262. PMID 30577475.
  14. ^ DING, Bao-yue; AO, lei; DING, Xue-ying; GAO, Jing; FAN, Wei; GAO, Shen (2010-04-13). "Active tumor targeting drug delivery system: the current status". Academic Journal of Second Military Medical University. 30 (3): 321–328. doi:10.3724/sp.j.1008.2010.00321. ISSN 0258-879X.
  15. ^ Palanikumar, L.; Al-Hosani, Sumaya; Kalmouni, Mona; Nguyen, Vanessa P.; Ali, Liaqat; Pasricha, Renu; Barrera, Francisco N.; Magzoub, Mazin (2020-03-03). "pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics". Communications Biology. 3 (1): 95. doi:10.1038/s42003-020-0817-4. ISSN 2399-3642. PMC 7054360. PMID 32127636.
  16. ^ Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, Liang XJ. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014 Jul-Aug;32(4):693-710. doi:10.1016/j.biotechadv.2013.11.009 Epub 2013 Dec 3. PMID 24309541.
  17. ^ Adepu, Shivakalyani; Ramakrishna, Seeram (January 2021). "Controlled Drug Delivery Systems: Current Status and Future Directions". Molecules. 26 (19): 5905. doi:10.3390/molecules26195905. ISSN 1420-3049. PMC 8512302. PMID 34641447.
  18. ^ Rizwan, Muhammad; Yahya, Rosiyah; Hassan, Aziz; Yar, Muhammad; Azzahari, Ahmad; Selvanathan, Vidhya; Sonsudin, Faridah; Abouloula, Cheyma (2017-04-12). "pH Sensitive Hydrogels in Drug Delivery: Brief History, Properties, Swelling, and Release Mechanism, Material Selection and Applications". Polymers. 9 (12): 137. doi:10.3390/polym9040137. ISSN 2073-4360. PMC 6432076. PMID 30970818.
  19. ^ a b c Cirillo G, Spizzirri UG, Curcio M, Nicoletta FP, Iemma F. Injectable Hydrogels for Cancer Therapy over the Last Decade. Pharmaceutics. 2019; 11(9):486. doi:10.3390/pharmaceutics11090486
  20. ^ Abulateefeh, S.R. Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic. Drug Deliv. and Transl. Res. (2022). doi:10.1007/s13346-022-01228-0
  21. ^ Torchilin, V (2006). "Multifunctional nanocarriers". Advanced Drug Delivery Reviews. 58 (14): 1532–55. doi:10.1016/j.addr.2006.09.009 PMID 17092599. S2CID 9464592
  22. ^ Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021 Nov 23;15(11):16982-17015. doi:10.1021/acsnano.1c04996 Epub 2021 Jun 28. PMID 34181394.
  23. ^ a b Paliwal, Shivani Rai; Paliwal, Rishi; Vyas, Suresh P. (2015-04-03). "A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery". Drug Delivery. 22 (3): 231–242. doi:10.3109/10717544.2014.882469. ISSN 1071-7544.
  24. ^ Lee, Y.; Thompson, D.H. (September 2017). "Stimuli‐responsive liposomes for drug delivery". WIREs Nanomedicine and Nanobiotechnology. 9 (5). doi:10.1002/wnan.1450. ISSN 1939-5116. PMC 5557698. PMID 28198148.
  25. ^ Song, Jian; Xu, Bingbing; Yao, Hui; Lu, Xiaofang; Tan, Yang; Wang, Bingyang; Wang, Xing; Yang, Zheng (2021). "Schiff-Linked PEGylated Doxorubicin Prodrug Forming pH-Responsive Nanoparticles With High Drug Loading and Effective Anticancer Therapy". Frontiers in Oncology. 11: 656717. doi:10.3389/fonc.2021.656717. ISSN 2234-943X. PMC 8027505. PMID 33842372.
  26. ^ Zhang, Xiaoli; Zhang, Tian; Ma, Xianbin; Wang, Yajun; Lu, Yi; Jia, Die; Huang, Xiaohua; Chen, Jiucun; Xu, Zhigang; Wen, Feiqiu (September 2020). "The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy". Asian Journal of Pharmaceutical Sciences. 15 (5): 605–616. doi:10.1016/j.ajps.2019.10.001. PMC 7610203. PMID 33193863.
  27. ^ a b c d Hoffman, Allan S. (2013-01-01). "Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation". Advanced Drug Delivery Reviews. Advanced Drug Delivery: Perspectives and Prospects. 65 (1): 10–16. doi:10.1016/j.addr.2012.11.004. ISSN 0169-409X. PMID 23246762.
  28. ^ Chien, Jenny Y.; Ho, Rodney J.Y. (January 2011). "Drug Delivery Trends in Clinical Trials and Translational Medicine: Evaluation of Pharmacokinetic Properties in Special Populations". Journal of Pharmaceutical Sciences. 100 (1): 53–58. doi:10.1002/jps.22253. PMC 4867146. PMID 20589750.
  29. ^ Wang, Lei; Niu, Xiuxiu; Song, Qingling; Jia, Jiajia; Hao, Yongwei; Zheng, Cuixia; Ding, Kaili; Xiao, Huifang; Liu, Xinxin; Zhang, Zhenzhong; Zhang, Yun (February 2020). "A two-step precise targeting nanoplatform for tumor therapy via the alkyl radicals activated by the microenvironment of organelles". Journal of Controlled Release. 318: 197–209. doi:10.1016/j.jconrel.2019.10.017. ISSN 0168-3659. PMID 31672622. S2CID 207814978.
  30. ^ Saw, Phei Er; Yao, Herui; Lin, Chunhao; Tao, Wei; Farokhzad, Omid C; Xu, Xiaoding (2019-08-05). "Stimuli-Responsive Polymer–Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy". Nano Letters. 19 (9): 5967–5974. doi:10.1021/acs.nanolett.9b01660. ISSN 1530-6984. PMID 31381852. S2CID 199451878.
Retrieved from "https://wiki.riteme.site/w/index.php?title=PH-responsive_tumor-targeted_drug_delivery&oldid=1241819062"